Protalix Biotherapeutics
Biotechnology, 1428 Brickell Ave, Miami, Florida, 33131, United States, 201-500 Employees
Phone Number: +14*********
Who is PROTALIX BIOTHERAPEUTICS
Protalix (NYSE American, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary p...
Read More
-
Headquarters: 1428 Brickell Ave, Miami, Florida, 33131, United States
-
Date Founded: 1994
-
Employees: 201-500
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 6211
|
NAICS Code: 424210 |
Show More
Does something look wrong? Fix it. | View contact records from PROTALIX BIOTHERAPEUTICS
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Protalix Biotherapeutics
Answer: Protalix Biotherapeutics's headquarters are located at 1428 Brickell Ave, Miami, Florida, 33131, United States
Answer: Protalix Biotherapeutics's phone number is +14*********
Answer: Protalix Biotherapeutics's official website is https://protalix.com
Answer: Protalix Biotherapeutics's revenue is $25 Million to $50 Million
Answer: Protalix Biotherapeutics's SIC: 6211
Answer: Protalix Biotherapeutics's NAICS: 424210
Answer: Protalix Biotherapeutics has 201-500 employees
Answer: Protalix Biotherapeutics is in Biotechnology
Answer: Protalix Biotherapeutics contact info: Phone number: +14********* Website: https://protalix.com
Answer: Protalix (NYSE American, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalixs unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalixs first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalixs development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human Galactosidase A protein for the treatment of Fabry disease; alidornase alfa or PRX 110, for the treatment of various human respiratory diseases or conditions; PRX 115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX 119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month